NEW YORK ( TheStreet) -- Shares of Repligen Corporation (Nasdaq: RGEN) were gapping down Thursday morning with an open price 38% lower than Wednesday's closing price. The stock closed at $7.26 Wednesday and opened today's trading at $4.50. The average volume for Repligen has been 116,400 shares per day over the past 30 days. Repligen has a market cap of $196.1 million and is part of the health care sector and drugs industry. Shares are up 109.2% year to date as of the close of trading on Wednesday. Repligen Corporation engages in the manufacture and supply of biologic products used to manufacture biologic drugs. TheStreet Ratings rates Repligen as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow, deteriorating net income and disappointing return on equity. You can view the full Repligen Ratings Report. Get more investment ideas from our investment research center.